Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V-306 RSV Vaccine in Healthy Women
NCT04519073Phase 1Completed
- Sponsor
- Virometix
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V-306 in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Virometix. Primary endpoints: Solicited local and general adverse events, Adverse events of special interest and 1 more. Started Sep 2020; status: completed.
02
Drugs
V-306
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04519073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519073.